Topical Capsaicin for Cyclical Vomiting

Cyclical Vomiting Clinical Trial

Official title:

Topical Capsaicin Cream for Treatment of Suspected Cyclical Vomiting Syndromes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03223350
• Other study ID #: 10658
• Status: Completed
• Phase: Phase 2
• Start date: December 20, 2017
• Est. completion date: August 5, 2019

Study information

• Verified date: December 2021
• Source: Henry Ford Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 randomized controlled trial testing the effect of topical capsaicin for the relieve of nausea and vomiting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 5, 2019
• Est. primary completion date: August 5, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• suspected cyclical vomiting syndrome / cannabinoid hyperemesis

• active severe nausea or vomiting in the emergency department

Exclusion Criteria:

• pregnant women, children < 18 years, no prior history of similar symptoms, suspected surgical or infectious cause of symptoms, suspected hepatitis or pancreatitis, allergy to capsaicin or hot peppers, chronic use of prescription antiemetic in prior 24 hours, abdominal pain alone (without nausea or vomiting)

Related Conditions & MeSH terms

• Cyclical Vomiting
• Vomiting

Intervention

Drug:
• Capsaicin 0.1% Cream
Topical application
• Placebos
placebo cream

Locations

Country	Name	City	State
United States	Henry Ford Hospital	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nausea Visual Analog Scale	Nausea visual analog scale, ranging from 0-100 mm, high measurement indicates worse nausea	30 minutes